


Tribenoside

Chemical Properties

CAS No. :	10310-32-4
Formula:	C ₂₉ H ₃₄ O ₆
Molecular Weight:	478.58
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Tribenoside (BG-356) is a vasoprotectant with mild anti-inflammatory, analgesic, and wound healing properties.
Targets(IC50)	Others,Histamine Receptor
In vitro	Administration of 1 nM-100 μM Tribenoside exhibits cytotoxic effect(EC50 = 13.74 μM) in HeLa cells[2].
In vivo	Oral administration in doses of 500 and 1,200 mg/kg Tribenoside weekly significantly decreases in the development of osteoporosis in male mice[3].

Solubility Information

Solubility	DMSO: 250 mg/mL (522.38 mM),Sonication is recommended. Ethanol: 30 mg/mL (62.69 mM),Sonication is recommended. DMF: 25 mg/mL (52.24 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 2 mg/mL (4.18 mM),Sonication is recommended. 10% DMSO+90% Saline: 10 mg/mL (20.9 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0895 mL	10.4476 mL	20.8951 mL
5 mM	0.4179 mL	2.0895 mL	4.179 mL
10 mM	0.209 mL	1.0448 mL	2.0895 mL
50 mM	0.0418 mL	0.209 mL	0.4179 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kikkawa Y, Takaki S, Matsuda Y, Okabe K, Taniguchi M, Oomachi K, Samejima T, Katagiri F, Hozumi K, Nomizu M. The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells. *Biol Pharm Bull.* 2010;33(2):307-10.

Yu-Chen Lo, et al. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. *Sci Rep.* 2017 Sep 12;7(1):11261.

G Wilhelmi, et al. Suitability of the C57 black mouse as an experimental animal for the study of skeletal changes due to ageing, with special reference to osteo-arthritis and its response to tribenoside. *Pharmacology.* 1976;14(4):289-96.

Kalbhen DA, Scherbach E, Felten K. [Histology of the antiarthritic effect of tribenoside in experimental gonarthrosis]. *Z Rheumatol.* 1981 Mar-Apr;40(2):72-86. German.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481